Filing Details

Accession Number:
0001104659-24-029534
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-29 21:54:13
Reporting Period:
2024-02-27
Accepted Time:
2024-02-29 21:54:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1763950 Lantern Pharma Inc. LTRN () TX
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1697316 Bios Fund I, Lp 1401 Foch Street
Suite 140
Fort Worth TX 76107
No No Yes No
1700297 Bios Fund I Qp, Lp 1401 Foch Street, Suite 140
Fort Worth TX 76107
No No Yes No
1714576 Bios Fund Ii, Lp 1401 Foch Street
Suite 140
Fort Worth TX 76107
No No Yes No
1716869 Bios Fund Ii Qp, Lp 1401 Foch Street
Suite 140
Fort Worth TX 76107
No No Yes No
1728851 Bios Fund Ii Nt, Lp 1401 Foch Street, Suite 140
Fort Worth TX 76107
No No Yes No
1789490 G.l. Aaron Fletcher C/O Lantern Pharma Inc.
1920 Mckinney Avenue, 7Th Floor
Dallas TX 75201
No No Yes No
1813313 Bios Equity Partners Ii, Lp 1751 River Run, Suite 400
Fort Worth TX 76107
No No Yes No
1813314 Bios Equity Partners, Lp 1751 River Run, Suite 400
Fort Worth TX 76107
No No Yes No
1813844 Bios Advisors Gp, Llc 1751 River Run
Suite 400
Fort Worth TX 76107
No No Yes No
1813845 Bios Capital Management, Lp 1751 River Run
Suite 400
Fort Worth TX 76107
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-02-27 4,649 $4.40 68,997 No 4 S Indirect By Bios Fund II NT, LP
Common Stock Disposition 2024-02-28 6,909 $4.85 62,088 No 4 S Indirect By Bios Fund II NT, LP
Common Stock Disposition 2024-02-29 1,832 $4.87 60,256 No 4 S Indirect By Bios Fund II NT, LP
Common Stock Disposition 2024-02-27 34,731 $4.40 515,412 No 4 S Indirect By Bios Fund II QP, LP
Common Stock Disposition 2024-02-28 51,608 $4.85 463,804 No 4 S Indirect By Bios Fund II QP, LP
Common Stock Disposition 2024-02-29 13,686 $4.87 450,118 No 4 S Indirect By Bios Fund II QP, LP
Common Stock Disposition 2024-02-27 10,620 $4.40 157,797 No 4 S Indirect By Bios Fund II, LP
Common Stock Disposition 2024-02-28 15,780 $4.85 142,017 No 4 S Indirect By Bios Fund II, LP
Common Stock Disposition 2024-02-29 4,185 $4.87 137,832 No 4 S Indirect By Bios Fund II, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Bios Fund II NT, LP
No 4 S Indirect By Bios Fund II NT, LP
No 4 S Indirect By Bios Fund II NT, LP
No 4 S Indirect By Bios Fund II QP, LP
No 4 S Indirect By Bios Fund II QP, LP
No 4 S Indirect By Bios Fund II QP, LP
No 4 S Indirect By Bios Fund II, LP
No 4 S Indirect By Bios Fund II, LP
No 4 S Indirect By Bios Fund II, LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 217,553 Indirect By Bios Fund I QP, LP
Common Stock 371,950 Indirect By Bios Fund I, LP
Common Stock 26,093 Indirect By BP Directors, LP
Footnotes
  1. The price reported in Column 4 is a weighted average price. On February 27, 2024 each of Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $4.35 to $4.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to (3) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. On February 28, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.60 to $5.21, inclusive.
  3. The price reported in Column 4 is a weighted average price. On February 29, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.62 to $5.33, inclusive.
  4. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
  5. Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
  6. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.